Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1031

Sort by

Sort Order Select

Journal Articles

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

Dai Chihara, Graça M. Dores, Christopher R. Flowers, Lindsay M. Morton

Blood (2021) 138 (9): 785–789.

https://doi.org/10.1182/blood.2020010497

Published: 2021

Includes: Supplemental data

Journal Articles

The rise of a new “great teacher”

Amanda B. McBride, Pierluigi Porcu

Blood (2021) 138 (3): 205–206.

https://doi.org/10.1182/blood.2021011754

Published: 2021

Journal Articles

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico

Blood (2021) 138 (3): 213–220.

https://doi.org/10.1182/blood.2020010387

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes for PTCL: which pathway to success?

Julie M. Vose

Blood (2021) 137 (19): 2570–2571.

https://doi.org/10.1182/blood.2020009850

Published: 2021

Journal Articles

Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia

Tomas Jelinek, Jana Zuchnicka

Blood (2020) 135 (20): 1816.

https://doi.org/10.1182/blood.2020005020

Published: 2020

Journal Articles

Brentuximab vedotin in the treatment of CD30 + PTCL

Stefan K. Barta, Jerald Z. Gong, Pierluigi Porcu

Blood (2019) 134 (26): 2339–2345.

https://doi.org/10.1182/blood.2019001821

Published: 2019

Journal Articles

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Blood (2019) 134 (24): 2159–2170.

https://doi.org/10.1182/blood.2019000779

Published: 2019

Includes: Supplemental data

Journal Articles

Subclassifying peripheral T-cell lymphoma NOS

Antonino Carbone, Annunziata Gloghini

Blood (2019) 134 (24): 2120–2121.

https://doi.org/10.1182/blood.2019003385

Published: 2019

Journal Articles

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

N. Nora Bennani, MD, Levi D Pederson, Pamela Atherton, Ivana Micallef, MD, Joseph P. Colgan, MD, Gita Thanarajasingam, MD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Stephen M Ansell, MD

Blood (2019) 134 (Supplement_1): 467.

https://doi.org/10.1182/blood-2019-126194

Published: 2019

Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 464.

https://doi.org/10.1182/blood-2019-122781

Published: 2019

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Blood (2019) 134 (Supplement_1): 468.

https://doi.org/10.1182/blood-2019-128513

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

LaQuisa C. Hill, MD, Rayne H. Rouce, MD, Tyler S. Smith, Lina Yang, PhD, Madhuwanti Srinivasan, Huimin Zhang, BS, Silvana Perconti, Birju Mehta, MS, BS, Olga Dakhova, Josalind Randall, Bambi J. Grilley, RPh, Helen E. Heslop, MD DSc, Malcolm K. Brenner, MD PhD, Maksim Mamonkin, PhD

Blood (2019) 134 (Supplement_1): 199.

https://doi.org/10.1182/blood-2019-129559

Published: 2019

Journal Articles

VAV1 Mutations Contributes to the Development of T-Cell Malignancies in Mice

Kota Fukumoto, MD, Mamiko Sakata-Yanagimoto, MD PhD, Manabu Fujisawa, MD, Tatsuhiro Sakamoto, MD PhD, Tran B. Nguyen, Sakurako Suma, MD, Hiroaki Miyoshi, MD PhD, Koichi Ohshima, MD PhD, Keisuke Kataoka, MD PhD, Seishi Ogawa, MD PhD, Shigeru Chiba, MD PhD

Blood (2019) 134 (Supplement_1): 300.

https://doi.org/10.1182/blood-2019-124591

Published: 2019

Journal Articles

Mogamulizumab within 55 Days of Allogeneic Transplant: A Report of 3 Cases

Mary Jo Lechowicz, MD, Dolores Caballero, MD PhD, Mollie Leoni, MD, Marilyn Tabachri, RN, BSN, Fiona Herr, PhD, Zanetta S. Lamar, MD

Blood (2019) 134 (Supplement_1): 5297.

https://doi.org/10.1182/blood-2019-129302

Published: 2019

Journal Articles

Hepatosplenic T Cell Lymphoma Case Report Presented with Hemphagocytosis Lymphohistiocytosis

Mohamed Abu Haleeqa, MBBS, Fatemah Alshehi, MBBS, Gannat Alghamrawi, MBBS, Lois Richard

Blood (2019) 134 (Supplement_1): 5363.

https://doi.org/10.1182/blood-2019-126445

Published: 2019

Journal Articles

Clinical Characteristic and Survival Outcome of Peripheral T Cell Lymphoma in a Chinese Population

Wenyu Li, MD PhD, Ling Huang, MD, Xinmiao Jiang, MD, Xiaojuan Wei, Hanguo Guo, Liu Sichu, MD, Chen Feili, MD, Zhanli Liang

Blood (2019) 134 (Supplement_1): 5271.

https://doi.org/10.1182/blood-2019-129552

Published: 2019

Journal Articles

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 5311.

https://doi.org/10.1182/blood-2019-129362

Published: 2019

Journal Articles

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Suvi-Katri Leivonen, PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Helle M Toldbod, PhD, Francesco d'Amore, MD PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5314.

https://doi.org/10.1182/blood-2019-129113

Published: 2019

NARROW

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

The rise of a new “great teacher”

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Outcomes for PTCL: which pathway to success?

Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia

Brentuximab vedotin in the treatment of CD30 + PTCL

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Subclassifying peripheral T-cell lymphoma NOS

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

VAV1 Mutations Contributes to the Development of T-Cell Malignancies in Mice

Mogamulizumab within 55 Days of Allogeneic Transplant: A Report of 3 Cases

Hepatosplenic T Cell Lymphoma Case Report Presented with Hemphagocytosis Lymphohistiocytosis

Clinical Characteristic and Survival Outcome of Peripheral T Cell Lymphoma in a Chinese Population

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only